MarketCap
Facebook
X
Telegram
Zoetis ROA Ratio | ZTS
Annual ROA Ratio Zoetis
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 17.28 | 17.46 | 16.41 | 14.16 | 14.65 | 12.04 | 12.99 | 13.25 | 10.06 | 10.73 | 4.28 | 8.82 | 7.69 | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 17.46 | 4.28 | 12.3 |
Quarterly ROA Ratio Zoetis
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 16.49 | 17.33 | 17.76 | 18.07 | 18.12 | 18.19 | 17.58 | 17.48 | 17.06 | 16.47 | 16.93 | 16.77 | 16.19 | 15.82 | 14.79 | 15.07 | 14.96 | 15.13 | 14.92 | 14.68 | 14.34 | 13.8 | 13.04 | 12.67 | 13.36 | 13.71 | 14.21 | 13.41 | 13.29 | 12.76 | 13.83 | 14.99 | 12.72 | 12.59 | 11.31 | 10.41 | 11.49 | 11.38 | 11.19 | 10.8 | 9.04 | 8.81 | 5.29 | 5.11 | 6.77 | 6.49 | 9.17 | 9.02 | 8.7 | 8.23 | 8.14 | 8.0 | 6.26 | 6.75 | 7.47 | 6.96 | 2.59 | 2.76 | 1.77 | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 18.19 | 1.77 | 12.08 |
ROA Ratio of other stocks in the Biotechnology industry
| Issuer | ROA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Arbutus Biopharma Corporation
ABUS
|
-35.41 | $ 3.8 | 2.15 % | $ 728 M |  Canada |
 |
Agenus
AGEN
|
-1.36 | $ 7.02 | -1.82 % | $ 209 M |  USA |
 |
AbCellera Biologics
ABCL
|
-10.79 | $ 12.44 | -0.52 % | $ 3.72 B | Canada |
 |
Artelo Biosciences
ARTL
|
-459.8 | $ 2.14 | 2.01 % | $ 405 K | USA |
 |
Immatics N.V.
IMTX
|
-34.93 | $ 6.42 | -0.23 % | $ 785 M |  Germany |
 |
Aptevo Therapeutics
APVO
|
-95.49 | $ 1.08 | -4.42 % | $ 341 K | USA |
 |
Aligos Therapeutics
ALGS
|
-27.33 | $ 2.59 | -34.43 % | $ 25.6 M | USA |
 |
Aclaris Therapeutics
ACRS
|
-40.46 | $ 4.13 | -2.5 % | $ 506 M | USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
-11.6 | $ 29.38 | -2.91 % | $ 4.46 B | USA |
 |
Cellectar Biosciences
CLRB
|
-145.48 | $ 1.24 | -3.15 % | $ 3.23 M | USA |
|
Larimar Therapeutics
LRMR
|
-113.6 | $ 2.68 | 5.93 % | $ 223 M | USA |
 |
Biofrontera AG
BFRA
|
-23.09 | - | -8.24 % | $ 105 M | Germany |
 |
Pliant Therapeutics
PLRX
|
66.29 | $ 0.78 | -2.19 % | $ 47.9 M | USA |
 |
Pharming Group N.V.
PHAR
|
9.69 | $ 13.02 | -1.06 % | $ 8.97 B |  Niderland |
 |
Catabasis Pharmaceuticals, Inc.
CATB
|
-78.6 | - | -6.97 % | $ 657 M | USA |
 |
Capricor Therapeutics
CAPR
|
-29.51 | $ 8.91 | -9.54 % | $ 414 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
6.02 | $ 29.06 | -1.09 % | $ 1.36 B | USA |
 |
China Biologic Products Holdings, Inc.
CBPO
|
6.74 | - | 1.68 % | $ 4.65 B |  China |
 |
Aquestive Therapeutics
AQST
|
-52.23 | $ 3.52 | -0.56 % | $ 376 M | USA |
 |
Jaguar Health
JAGX
|
-0.14 | $ 0.44 | -0.21 % | $ 1.03 M | USA |
 |
Arvinas
ARVN
|
-11.28 | $ 6.9 | 2.07 % | $ 489 M | USA |
 |
Cerus Corporation
CERS
|
-7.04 | $ 1.95 | -6.04 % | $ 372 M | USA |
 |
Beam Therapeutics
BEAM
|
-5.4 | $ 25.16 | -6.88 % | $ 2.49 B | USA |
 |
Pulmatrix
PULM
|
-26.07 | $ 1.39 | 2.58 % | $ 5.08 B | USA |
 |
Fortress Biotech
FBIO
|
19.94 | $ 1.9 | -4.52 % | $ 53 M | USA |
 |
Inhibrx
INBX
|
-78.39 | $ 90.63 | -1.21 % | $ 4.27 B | USA |
 |
Entera Bio Ltd.
ENTX
|
-71.53 | $ 3.24 | -0.31 % | $ 150 M |  Israel |
 |
Flexion Therapeutics, Inc.
FLXN
|
-45.13 | - | - | $ 459 M | USA |
 |
Legend Biotech Corporation
LEGN
|
-17.12 | $ 20.25 | -16.63 % | $ 7.46 B | USA |
 |
CytomX Therapeutics
CTMX
|
-11.46 | $ 2.0 | 0.76 % | $ 276 M | USA |
 |
Krystal Biotech
KRYS
|
15.36 | $ 306.47 | 1.13 % | $ 8.87 B | USA |
 |
Kura Oncology
KURA
|
-37.74 | $ 7.56 | -0.13 % | $ 663 M | USA |
 |
Inhibikase Therapeutics
IKT
|
-26.63 | $ 1.58 | -6.25 % | $ 155 M | USA |
 |
Heron Therapeutics
HRTX
|
-7.82 | $ 0.38 | 1.38 % | $ 63.3 M | USA |
 |
Inovio Pharmaceuticals
INO
|
-114.39 | $ 1.47 | -2.98 % | $ 68.9 M | USA |
 |
Corvus Pharmaceuticals
CRVS
|
-21.51 | $ 11.36 | 0.09 % | $ 897 M | USA |
 |
Aytu BioScience
AYTU
|
-13.57 | $ 1.83 | 2.23 % | $ 22.5 M | USA |
 |
Heat Biologics, Inc.
HTBX
|
-20.97 | - | -5.76 % | $ 99.8 M | USA |
 |
Innoviva
INVA
|
16.58 | $ 19.08 | 0.39 % | $ 1.29 B | USA |
 |
BioCardia
BCDA
|
-241.08 | $ 0.95 | 2.66 % | $ 6.33 M | USA |
 |
Kindred Biosciences, Inc.
KIN
|
-22.75 | - | 0.11 % | $ 419 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
-26.39 | $ 2.3 | -5.35 % | $ 14.7 B |  Australia |
 |
Shineco, Inc.
TYHT
|
-8.38 | - | -3.90 % | $ 97.2 M | China |
 |
Millendo Therapeutics, Inc.
MLND
|
-83.87 | - | -5.36 % | $ 20.2 M | USA |
 |
Certara
CERT
|
-0.1 | $ 12.21 | -0.08 % | $ 1.96 B | USA |
 |
Dyadic International
DYAI
|
-74.05 | $ 0.39 | 1.16 % | $ 14.1 M | USA |
 |
Intec Pharma Ltd
NTEC
|
-67.61 | - | -12.45 % | $ 17.7 M | Israel |
 |
Anika Therapeutics
ANIK
|
-5.78 | $ 13.42 | -7.89 % | $ 192 M | USA |
 |
Aprea Therapeutics
APRE
|
-79.08 | $ 0.45 | -9.44 % | $ 2.94 M | USA |
 |
Galectin Therapeutics
GALT
|
-157.87 | $ 3.4 | -1.73 % | $ 217 M | USA |